ns-MRAs: The Cardiovascular-Kidney-Metabolic Connection
Csaba P. Kovesdy, MD
Finnian R. Mc Causland, MD
ns-MRAs and eGFR Slope: The Kidney Perspective
FCS and SHTG: Are We Meeting the Need?
Ira J. Goldberg, MD
Kausik Ray, MBChB, MD, MPhil
Christie Ballantyne, MD
Mastering MRA Monitoring: The Key to Success
Akshay S. Desai, MD
John McMurray, MD
Optimizing HF Outcomes Across the Spectrum: Emerging Evidence
Novel oral LDL-c lowering therapies on the horizon: CETP inhibition
Ulrich Laufs, MD, PhD
Reaching LDL-c targets in patients at high CV risk: How well are we doing?
Julia Brandts, MD
A multidisciplinary clinical dialogue: Optimizing long-term goals: practical approaches to novel potassium binder use in cardiorenal care
James Burton, DM, FRCP
Aaron Wong, MD
The remaining challenges in lowering LDL-c in patients at increased CV risk
Prof. Kausik Ray
Clinical choices in managing LDL-c: Where do novel therapies fit in?
Pasquale Perrone-Filardi, MD, PhD
Challenges of managing hyperkalemia in HF patients with CKD while maintaining RAAS inhibitor therapy
Gianluigi Savarese, MD
Summarizing multidisciplinary strategies: Where do we go from here?
Strategies for managing hyperkalemia in cardiorenal disease: A clinical dialogue defining a roadmap to improved outcomes
The case for early LDL-c lowering in patients at increased CV risk: When should we start?
New Horizons: Unraveling Novel Therapies for Enhanced Cardiovascular Outcomes in Patients With Heart Failure
Carolyn S. P. Lam, MBBS, PhD, MRCP, MS, FACC, FAMS, FESC
Scott Solomon, MD
Mikhail Kosiborod, MD
Managing a patient with residual risk: Applying recent evidence with EPA to practice
Loading...
We're glad to see you're enjoying PACE-CME… but how about a more personalized experience?
Press cancel to remain on PACE-CME. Press the link below or the continue button to keep going.